Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2012; 18(12): 1357-1364
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Table 3 Chemotherapy regimens in second line
| Cisplatin group | Irinotecan group | Oxaliplatin group | Other group | P value | |
| Number of patient | 23 (28.8%) | 22 (27.5%) | 21 (26.3%) | 14 (17.5%) | NS |
| Median number of cycle | 5.0 (1.0-10.0) | 5.0 (1.0-12.0) | 4.0 (1.0-12.0) | 2.0 (1.0-5.0) | NS |
| Median duration of treatment (mo) | 2.7 (0.5-6.9) | 3.2 (0.3-7.4) | 2.3 (0.6-7.1) | 2.3 (0.3-7.4) | NS |
| Disease control rate | 10 (43.5%) | 9 (40.9%) | 9 (42.9%) | 4 (28.6%) | NS |
| OS (mo) | 6.7 (3.2-9.3) | 4.5 (3.2-6.4) | 4.5 (2.6-9.6) | 5.2 (3.8-15.8) | NS |
| PFS (mo) | 4.1 (1.9-6.7) | 3.0 (2.0-6.1) | 2.6 (1.8-5.4) | 2.4 (2.1-10.1) | NS |
- Citation: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364
- URL: https://www.wjgnet.com/1007-9327/full/v18/i12/1357.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i12.1357